Clinical trial
A Multi-center, Prospective, Observational Study to Evaluate Therapeutic Effectiveness and Safety of Kabalin Cap. in Patients With Neuropathic Pain
NCT07930260 is registered in ClinicalTrials.gov with HK inno.N Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Prospective, Observational Study to Evaluate Therapeutic Effectiveness and Safety of Kabalin Cap. in Patients With Neuropathic Pain
- Lead sponsor
- HK inno.N Corporation
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- February 27, 2025
- Completion date
- June 30, 2028
- Enrollment
- 5,217 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
peripheral or central neuropathic pain
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Proportion of participants with a ≥50% improvement in pain severity from baseline at Week 12
The proportion of participants whose pain severity score, as assessed using the SF-MPQ, shows a ≥50% improvement from baseline after 12 weeks of treatment with Kabalin Cap. will be reported
Lead sponsor's other trials
HK inno.N Corporation, most recent start first.
+98 more trials See the organization page
Similar trials
Same condition (Neuralgia) and phase, most recent start first.
+219 more trials See the condition page